GlutaredoxinV1, Main, Exploration, bibRecord, 000484

Coenzyme Q10 and oxidative stress, the association with peripheral sensory neuropathy and cardiovascular disease in type 2 diabetes mellitus.

Identifieur interne : 000484 ( Main/Exploration ); précédent : 000483; suivant : 000485

Coenzyme Q10 and oxidative stress, the association with peripheral sensory neuropathy and cardiovascular disease in type 2 diabetes mellitus.

Auteurs : Elisabete Forsberg [Suède] ; Cheng Xu [Suède] ; Jacob Grünler [Suède] ; Johan Frosteg Rd [Suède] ; Michael Tekle [Suède] ; Kerstin Brismar [Suède] ; Lars K Rvestedt [Suède]

Source :

Journal of diabetes and its complications [ 1873-460X ]

RBID : pubmed:26395643

Descripteurs français

KwdFr :
- Adulte d'âge moyen (MeSH), Angiopathies diabétiques (épidémiologie), Angiopathies diabétiques (étiologie), Cardiomyopathies diabétiques (épidémiologie), Cardiomyopathies diabétiques (étiologie), Diabète de type 2 (complications), Diabète de type 2 (immunologie), Diabète de type 2 (sang), Diabète de type 2 (thérapie), Facteurs de risque (MeSH), Facteurs sexuels (MeSH), Femelle (MeSH), Humains (MeSH), Hyperlipidémies (complications), Hyperlipidémies (physiopathologie), Hyperlipidémies (épidémiologie), Hémoglobine A glycosylée (analyse), Maladies cardiovasculaires (complications), Maladies cardiovasculaires (épidémiologie), Maladies cardiovasculaires (étiologie), Mâle (MeSH), Neuropathies diabétiques (épidémiologie), Neuropathies diabétiques (étiologie), Néphropathies diabétiques (épidémiologie), Néphropathies diabétiques (étiologie), Prévalence (MeSH), Régulation négative (MeSH), Stress oxydatif (MeSH), Surpoids (complications), Surpoids (physiopathologie), Surpoids (épidémiologie), Suède (épidémiologie), Tour de taille (MeSH), Ubiquinones (analogues et dérivés), Ubiquinones (sang), Études de cohortes (MeSH).
MESH :
- analogues et dérivés : Ubiquinones.
- analyse : Hémoglobine A glycosylée.
- immunologie : Diabète de type 2.
- physiopathologie : Hyperlipidémies, Surpoids.
- sang : Diabète de type 2, Hyperlipidémies, Maladies cardiovasculaires, Surpoids, Ubiquinones.
- thérapie : Diabète de type 2.
- épidémiologie : Angiopathies diabétiques, Cardiomyopathies diabétiques, Hyperlipidémies, Maladies cardiovasculaires, Neuropathies diabétiques, Néphropathies diabétiques, Surpoids, Suède.
- étiologie : Angiopathies diabétiques, Cardiomyopathies diabétiques, Maladies cardiovasculaires, Neuropathies diabétiques, Néphropathies diabétiques.
- Adulte d'âge moyen, Facteurs de risque, Facteurs sexuels, Femelle, Humains, Mâle, Prévalence, Régulation négative, Stress oxydatif, Tour de taille, Études de cohortes.

English descriptors

KwdEn :
- Cardiovascular Diseases (complications), Cardiovascular Diseases (epidemiology), Cardiovascular Diseases (etiology), Cohort Studies (MeSH), Diabetes Mellitus, Type 2 (blood), Diabetes Mellitus, Type 2 (complications), Diabetes Mellitus, Type 2 (immunology), Diabetes Mellitus, Type 2 (therapy), Diabetic Angiopathies (epidemiology), Diabetic Angiopathies (etiology), Diabetic Cardiomyopathies (epidemiology), Diabetic Cardiomyopathies (etiology), Diabetic Nephropathies (epidemiology), Diabetic Nephropathies (etiology), Diabetic Neuropathies (epidemiology), Diabetic Neuropathies (etiology), Down-Regulation (MeSH), Female (MeSH), Glycated Hemoglobin A (analysis), Humans (MeSH), Hyperlipidemias (complications), Hyperlipidemias (epidemiology), Hyperlipidemias (physiopathology), Male (MeSH), Middle Aged (MeSH), Overweight (complications), Overweight (epidemiology), Overweight (physiopathology), Oxidative Stress (MeSH), Prevalence (MeSH), Risk Factors (MeSH), Sex Factors (MeSH), Sweden (epidemiology), Ubiquinone (analogs & derivatives), Ubiquinone (blood), Waist Circumference (MeSH).
MESH :
- chemical , analogs & derivatives : Ubiquinone.
- chemical , analysis : Glycated Hemoglobin A.
- blood : Diabetes Mellitus, Type 2, Ubiquinone.
- complications : Cardiovascular Diseases, Diabetes Mellitus, Type 2, Hyperlipidemias, Overweight.
- epidemiology : Cardiovascular Diseases, Diabetic Angiopathies, Diabetic Cardiomyopathies, Diabetic Nephropathies, Diabetic Neuropathies, Hyperlipidemias, Overweight, Sweden.
- etiology : Cardiovascular Diseases, Diabetic Angiopathies, Diabetic Cardiomyopathies, Diabetic Nephropathies, Diabetic Neuropathies.
- immunology : Diabetes Mellitus, Type 2.
- physiopathology : Hyperlipidemias, Overweight.
- therapy : Diabetes Mellitus, Type 2.
- Cohort Studies, Down-Regulation, Female, Humans, Male, Middle Aged, Oxidative Stress, Prevalence, Risk Factors, Sex Factors, Waist Circumference.

Abstract

OBJECTIVE

Our study aimed to explore associations between metabolic control, oxidative stress and coenzyme Q10 (CoQ10) in relation to diabetes complications in a representative population of type 2 diabetes.

RESEARCH DESIGN AND METHODS

A geographic cohort of 156 subjects was recruited. Serum concentrations of CoQ10 and vitamin E were measured by HPLC. ROS was determined by free oxygen radicals testing (FORT). Glutaredoxin (Grx) activity, oxidized LDL cholesterol (oxLDLc), high sensitive CRP (hsCRP), HbA1c, urine albumin, serum creatinine, serum cystatin C, and plasma lipids were assayed with routine laboratory protocols.

RESULTS

Serum CoQ10 was higher than in nondiabetics. HbA1c, fP-glucose, hyperlipidemia, inflammation (hsCRP), and increased BMI were associated with signs of oxidative stress as increased levels of FORT, Grx activity and/or increased levels of oxLDLc Oxidative stress was found to be strongly correlated with prevalence of cardiovascular disease (CVD) and peripheral sensory neuropathy (PSN). In both gender groups there were positive correlations between CoQ10 and oxLDLc, and between BMI and the ratio CoQ10/chol. Grx activity was inversely correlated to oxLDLc and CoQ10. Women with CVD and PSN had higher waist index, oxLDLc, and FORT levels compared to men but lower CoQ10 levels. Men had worse kidney function and lower vitamin E. Multiple regression analysis showed increased levels of CoQ10 to be significantly correlated with increased levels of cholesterol, triglycerides, vitamin E, fB-glucose and BMI.

CONCLUSIONS

Hyperlipidemia, hyperglycemia and inflammation were associated with oxidative stress, which was correlated to the prevalence of diabetes complications. CoQ10 was increased in response to oxidative stress. There were gender differences in the risk factors associated with diabetes complications.

DOI: 10.1016/j.jdiacomp.2015.08.006
PubMed: 26395643

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000499
to stream Main, to step Curation: 000499

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Coenzyme Q10 and oxidative stress, the association with peripheral sensory neuropathy and cardiovascular disease in type 2 diabetes mellitus.</title>
<author><name sortKey="Forsberg, Elisabete" sort="Forsberg, Elisabete" uniqKey="Forsberg E" first="Elisabete" last="Forsberg">Elisabete Forsberg</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Molecular Medicine and Surgery, The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Molecular Medicine and Surgery, The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Xu, Cheng" sort="Xu, Cheng" uniqKey="Xu C" first="Cheng" last="Xu">Cheng Xu</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Molecular Medicine and Surgery, The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden. Electronic address: cheng.xu@ki.se.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Molecular Medicine and Surgery, The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Grunler, Jacob" sort="Grunler, Jacob" uniqKey="Grunler J" first="Jacob" last="Grünler">Jacob Grünler</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Molecular Medicine and Surgery, The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Molecular Medicine and Surgery, The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Frosteg Rd, Johan" sort="Frosteg Rd, Johan" uniqKey="Frosteg Rd J" first="Johan" last="Frosteg Rd">Johan Frosteg Rd</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medicine, Huddinge, Karolinska University Hospital, Stockholm, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Medicine, Huddinge, Karolinska University Hospital, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tekle, Michael" sort="Tekle, Michael" uniqKey="Tekle M" first="Michael" last="Tekle">Michael Tekle</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Molecular Medicine and Surgery, The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Molecular Medicine and Surgery, The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brismar, Kerstin" sort="Brismar, Kerstin" uniqKey="Brismar K" first="Kerstin" last="Brismar">Kerstin Brismar</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Molecular Medicine and Surgery, The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden. Electronic address: kerstin.brismar@ki.se.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Molecular Medicine and Surgery, The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="K Rvestedt, Lars" sort="K Rvestedt, Lars" uniqKey="K Rvestedt L" first="Lars" last="K Rvestedt">Lars K Rvestedt</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Molecular Medicine and Surgery, The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden; Stockholms Sjukhem, Stockholm, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Molecular Medicine and Surgery, The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden; Stockholms Sjukhem, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015 Nov-Dec</date>
<idno type="RBID">pubmed:26395643</idno>
<idno type="pmid">26395643</idno>
<idno type="doi">10.1016/j.jdiacomp.2015.08.006</idno>
<idno type="wicri:Area/Main/Corpus">000499</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000499</idno>
<idno type="wicri:Area/Main/Curation">000499</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000499</idno>
<idno type="wicri:Area/Main/Exploration">000499</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Coenzyme Q10 and oxidative stress, the association with peripheral sensory neuropathy and cardiovascular disease in type 2 diabetes mellitus.</title>
<author><name sortKey="Forsberg, Elisabete" sort="Forsberg, Elisabete" uniqKey="Forsberg E" first="Elisabete" last="Forsberg">Elisabete Forsberg</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Molecular Medicine and Surgery, The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Molecular Medicine and Surgery, The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Xu, Cheng" sort="Xu, Cheng" uniqKey="Xu C" first="Cheng" last="Xu">Cheng Xu</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Molecular Medicine and Surgery, The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden. Electronic address: cheng.xu@ki.se.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Molecular Medicine and Surgery, The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Grunler, Jacob" sort="Grunler, Jacob" uniqKey="Grunler J" first="Jacob" last="Grünler">Jacob Grünler</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Molecular Medicine and Surgery, The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Molecular Medicine and Surgery, The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Frosteg Rd, Johan" sort="Frosteg Rd, Johan" uniqKey="Frosteg Rd J" first="Johan" last="Frosteg Rd">Johan Frosteg Rd</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medicine, Huddinge, Karolinska University Hospital, Stockholm, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Medicine, Huddinge, Karolinska University Hospital, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tekle, Michael" sort="Tekle, Michael" uniqKey="Tekle M" first="Michael" last="Tekle">Michael Tekle</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Molecular Medicine and Surgery, The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Molecular Medicine and Surgery, The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brismar, Kerstin" sort="Brismar, Kerstin" uniqKey="Brismar K" first="Kerstin" last="Brismar">Kerstin Brismar</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Molecular Medicine and Surgery, The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden. Electronic address: kerstin.brismar@ki.se.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Molecular Medicine and Surgery, The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="K Rvestedt, Lars" sort="K Rvestedt, Lars" uniqKey="K Rvestedt L" first="Lars" last="K Rvestedt">Lars K Rvestedt</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Molecular Medicine and Surgery, The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden; Stockholms Sjukhem, Stockholm, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Molecular Medicine and Surgery, The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden; Stockholms Sjukhem, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of diabetes and its complications</title>
<idno type="eISSN">1873-460X</idno>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cardiovascular Diseases (complications)</term>
<term>Cardiovascular Diseases (epidemiology)</term>
<term>Cardiovascular Diseases (etiology)</term>
<term>Cohort Studies (MeSH)</term>
<term>Diabetes Mellitus, Type 2 (blood)</term>
<term>Diabetes Mellitus, Type 2 (complications)</term>
<term>Diabetes Mellitus, Type 2 (immunology)</term>
<term>Diabetes Mellitus, Type 2 (therapy)</term>
<term>Diabetic Angiopathies (epidemiology)</term>
<term>Diabetic Angiopathies (etiology)</term>
<term>Diabetic Cardiomyopathies (epidemiology)</term>
<term>Diabetic Cardiomyopathies (etiology)</term>
<term>Diabetic Nephropathies (epidemiology)</term>
<term>Diabetic Nephropathies (etiology)</term>
<term>Diabetic Neuropathies (epidemiology)</term>
<term>Diabetic Neuropathies (etiology)</term>
<term>Down-Regulation (MeSH)</term>
<term>Female (MeSH)</term>
<term>Glycated Hemoglobin A (analysis)</term>
<term>Humans (MeSH)</term>
<term>Hyperlipidemias (complications)</term>
<term>Hyperlipidemias (epidemiology)</term>
<term>Hyperlipidemias (physiopathology)</term>
<term>Male (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Overweight (complications)</term>
<term>Overweight (epidemiology)</term>
<term>Overweight (physiopathology)</term>
<term>Oxidative Stress (MeSH)</term>
<term>Prevalence (MeSH)</term>
<term>Risk Factors (MeSH)</term>
<term>Sex Factors (MeSH)</term>
<term>Sweden (epidemiology)</term>
<term>Ubiquinone (analogs & derivatives)</term>
<term>Ubiquinone (blood)</term>
<term>Waist Circumference (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen (MeSH)</term>
<term>Angiopathies diabétiques (épidémiologie)</term>
<term>Angiopathies diabétiques (étiologie)</term>
<term>Cardiomyopathies diabétiques (épidémiologie)</term>
<term>Cardiomyopathies diabétiques (étiologie)</term>
<term>Diabète de type 2 (complications)</term>
<term>Diabète de type 2 (immunologie)</term>
<term>Diabète de type 2 (sang)</term>
<term>Diabète de type 2 (thérapie)</term>
<term>Facteurs de risque (MeSH)</term>
<term>Facteurs sexuels (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Hyperlipidémies (complications)</term>
<term>Hyperlipidémies (physiopathologie)</term>
<term>Hyperlipidémies (épidémiologie)</term>
<term>Hémoglobine A glycosylée (analyse)</term>
<term>Maladies cardiovasculaires (complications)</term>
<term>Maladies cardiovasculaires (épidémiologie)</term>
<term>Maladies cardiovasculaires (étiologie)</term>
<term>Mâle (MeSH)</term>
<term>Neuropathies diabétiques (épidémiologie)</term>
<term>Neuropathies diabétiques (étiologie)</term>
<term>Néphropathies diabétiques (épidémiologie)</term>
<term>Néphropathies diabétiques (étiologie)</term>
<term>Prévalence (MeSH)</term>
<term>Régulation négative (MeSH)</term>
<term>Stress oxydatif (MeSH)</term>
<term>Surpoids (complications)</term>
<term>Surpoids (physiopathologie)</term>
<term>Surpoids (épidémiologie)</term>
<term>Suède (épidémiologie)</term>
<term>Tour de taille (MeSH)</term>
<term>Ubiquinones (analogues et dérivés)</term>
<term>Ubiquinones (sang)</term>
<term>Études de cohortes (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Ubiquinone</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Glycated Hemoglobin A</term>
</keywords>
<keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Ubiquinones</term>
</keywords>
<keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Hémoglobine A glycosylée</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Diabetes Mellitus, Type 2</term>
<term>Ubiquinone</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Cardiovascular Diseases</term>
<term>Diabetes Mellitus, Type 2</term>
<term>Hyperlipidemias</term>
<term>Overweight</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Cardiovascular Diseases</term>
<term>Diabetic Angiopathies</term>
<term>Diabetic Cardiomyopathies</term>
<term>Diabetic Nephropathies</term>
<term>Diabetic Neuropathies</term>
<term>Hyperlipidemias</term>
<term>Overweight</term>
<term>Sweden</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Cardiovascular Diseases</term>
<term>Diabetic Angiopathies</term>
<term>Diabetic Cardiomyopathies</term>
<term>Diabetic Nephropathies</term>
<term>Diabetic Neuropathies</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Diabète de type 2</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Diabetes Mellitus, Type 2</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Hyperlipidémies</term>
<term>Surpoids</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Hyperlipidemias</term>
<term>Overweight</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Diabète de type 2</term>
<term>Hyperlipidémies</term>
<term>Maladies cardiovasculaires</term>
<term>Surpoids</term>
<term>Ubiquinones</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Diabetes Mellitus, Type 2</term>
</keywords>
<keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Diabète de type 2</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Angiopathies diabétiques</term>
<term>Cardiomyopathies diabétiques</term>
<term>Hyperlipidémies</term>
<term>Maladies cardiovasculaires</term>
<term>Neuropathies diabétiques</term>
<term>Néphropathies diabétiques</term>
<term>Surpoids</term>
<term>Suède</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Angiopathies diabétiques</term>
<term>Cardiomyopathies diabétiques</term>
<term>Maladies cardiovasculaires</term>
<term>Neuropathies diabétiques</term>
<term>Néphropathies diabétiques</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Cohort Studies</term>
<term>Down-Regulation</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Oxidative Stress</term>
<term>Prevalence</term>
<term>Risk Factors</term>
<term>Sex Factors</term>
<term>Waist Circumference</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Facteurs de risque</term>
<term>Facteurs sexuels</term>
<term>Femelle</term>
<term>Humains</term>
<term>Mâle</term>
<term>Prévalence</term>
<term>Régulation négative</term>
<term>Stress oxydatif</term>
<term>Tour de taille</term>
<term>Études de cohortes</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b>
</p>
<p>Our study aimed to explore associations between metabolic control, oxidative stress and coenzyme Q10 (CoQ10) in relation to diabetes complications in a representative population of type 2 diabetes.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESEARCH DESIGN AND METHODS</b>
</p>
<p>A geographic cohort of 156 subjects was recruited. Serum concentrations of CoQ10 and vitamin E were measured by HPLC. ROS was determined by free oxygen radicals testing (FORT). Glutaredoxin (Grx) activity, oxidized LDL cholesterol (oxLDLc), high sensitive CRP (hsCRP), HbA1c, urine albumin, serum creatinine, serum cystatin C, and plasma lipids were assayed with routine laboratory protocols.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>Serum CoQ10 was higher than in nondiabetics. HbA1c, fP-glucose, hyperlipidemia, inflammation (hsCRP), and increased BMI were associated with signs of oxidative stress as increased levels of FORT, Grx activity and/or increased levels of oxLDLc Oxidative stress was found to be strongly correlated with prevalence of cardiovascular disease (CVD) and peripheral sensory neuropathy (PSN). In both gender groups there were positive correlations between CoQ10 and oxLDLc, and between BMI and the ratio CoQ10/chol. Grx activity was inversely correlated to oxLDLc and CoQ10. Women with CVD and PSN had higher waist index, oxLDLc, and FORT levels compared to men but lower CoQ10 levels. Men had worse kidney function and lower vitamin E. Multiple regression analysis showed increased levels of CoQ10 to be significantly correlated with increased levels of cholesterol, triglycerides, vitamin E, fB-glucose and BMI.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b>
</p>
<p>Hyperlipidemia, hyperglycemia and inflammation were associated with oxidative stress, which was correlated to the prevalence of diabetes complications. CoQ10 was increased in response to oxidative stress. There were gender differences in the risk factors associated with diabetes complications.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26395643</PMID>
<DateCompleted><Year>2016</Year>
<Month>09</Month>
<Day>12</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>11</Month>
<Day>16</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-460X</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>29</Volume>
<Issue>8</Issue>
<PubDate><MedlineDate>2015 Nov-Dec</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Journal of diabetes and its complications</Title>
<ISOAbbreviation>J Diabetes Complications</ISOAbbreviation>
</Journal>
<ArticleTitle>Coenzyme Q10 and oxidative stress, the association with peripheral sensory neuropathy and cardiovascular disease in type 2 diabetes mellitus.</ArticleTitle>
<Pagination><MedlinePgn>1152-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jdiacomp.2015.08.006</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S1056-8727(15)00351-7</ELocationID>
<Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Our study aimed to explore associations between metabolic control, oxidative stress and coenzyme Q10 (CoQ10) in relation to diabetes complications in a representative population of type 2 diabetes.</AbstractText>
<AbstractText Label="RESEARCH DESIGN AND METHODS" NlmCategory="METHODS">A geographic cohort of 156 subjects was recruited. Serum concentrations of CoQ10 and vitamin E were measured by HPLC. ROS was determined by free oxygen radicals testing (FORT). Glutaredoxin (Grx) activity, oxidized LDL cholesterol (oxLDLc), high sensitive CRP (hsCRP), HbA1c, urine albumin, serum creatinine, serum cystatin C, and plasma lipids were assayed with routine laboratory protocols.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Serum CoQ10 was higher than in nondiabetics. HbA1c, fP-glucose, hyperlipidemia, inflammation (hsCRP), and increased BMI were associated with signs of oxidative stress as increased levels of FORT, Grx activity and/or increased levels of oxLDLc Oxidative stress was found to be strongly correlated with prevalence of cardiovascular disease (CVD) and peripheral sensory neuropathy (PSN). In both gender groups there were positive correlations between CoQ10 and oxLDLc, and between BMI and the ratio CoQ10/chol. Grx activity was inversely correlated to oxLDLc and CoQ10. Women with CVD and PSN had higher waist index, oxLDLc, and FORT levels compared to men but lower CoQ10 levels. Men had worse kidney function and lower vitamin E. Multiple regression analysis showed increased levels of CoQ10 to be significantly correlated with increased levels of cholesterol, triglycerides, vitamin E, fB-glucose and BMI.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Hyperlipidemia, hyperglycemia and inflammation were associated with oxidative stress, which was correlated to the prevalence of diabetes complications. CoQ10 was increased in response to oxidative stress. There were gender differences in the risk factors associated with diabetes complications.</AbstractText>
<CopyrightInformation>Copyright © 2015 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Forsberg</LastName>
<ForeName>Elisabete</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Department of Molecular Medicine and Surgery, The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Xu</LastName>
<ForeName>Cheng</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Department of Molecular Medicine and Surgery, The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden. Electronic address: cheng.xu@ki.se.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Grünler</LastName>
<ForeName>Jacob</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Department of Molecular Medicine and Surgery, The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Frostegård</LastName>
<ForeName>Johan</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, Huddinge, Karolinska University Hospital, Stockholm, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tekle</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Department of Molecular Medicine and Surgery, The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Brismar</LastName>
<ForeName>Kerstin</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Department of Molecular Medicine and Surgery, The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden. Electronic address: kerstin.brismar@ki.se.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kärvestedt</LastName>
<ForeName>Lars</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Department of Molecular Medicine and Surgery, The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden; Stockholms Sjukhem, Stockholm, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2015</Year>
<Month>08</Month>
<Day>13</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Diabetes Complications</MedlineTA>
<NlmUniqueID>9204583</NlmUniqueID>
<ISSNLinking>1056-8727</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006442">Glycated Hemoglobin A</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C517652">hemoglobin A1c protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>1339-63-5</RegistryNumber>
<NameOfSubstance UI="D014451">Ubiquinone</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EJ27X76M46</RegistryNumber>
<NameOfSubstance UI="C024989">coenzyme Q10</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003925" MajorTopicYN="N">Diabetic Angiopathies</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058065" MajorTopicYN="N">Diabetic Cardiomyopathies</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003928" MajorTopicYN="N">Diabetic Nephropathies</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003929" MajorTopicYN="N">Diabetic Neuropathies</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015536" MajorTopicYN="Y">Down-Regulation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006442" MajorTopicYN="N">Glycated Hemoglobin A</DescriptorName>
<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006949" MajorTopicYN="N">Hyperlipidemias</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D050177" MajorTopicYN="N">Overweight</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018384" MajorTopicYN="Y">Oxidative Stress</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013548" MajorTopicYN="N">Sweden</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014451" MajorTopicYN="N">Ubiquinone</DescriptorName>
<QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055105" MajorTopicYN="N">Waist Circumference</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiovascular disease</Keyword>
<Keyword MajorTopicYN="N">Coenzyme Q10</Keyword>
<Keyword MajorTopicYN="N">Diabetes complications</Keyword>
<Keyword MajorTopicYN="N">Oxidative stress</Keyword>
<Keyword MajorTopicYN="N">Peripheral sensory neuropathy</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year>
<Month>02</Month>
<Day>19</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2015</Year>
<Month>07</Month>
<Day>09</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2015</Year>
<Month>08</Month>
<Day>05</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2015</Year>
<Month>9</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2015</Year>
<Month>9</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>9</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">26395643</ArticleId>
<ArticleId IdType="pii">S1056-8727(15)00351-7</ArticleId>
<ArticleId IdType="doi">10.1016/j.jdiacomp.2015.08.006</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Suède</li>
</country>
<region><li>Svealand</li>
</region>
<settlement><li>Stockholm</li>
</settlement>
</list>
<tree><country name="Suède"><region name="Svealand"><name sortKey="Forsberg, Elisabete" sort="Forsberg, Elisabete" uniqKey="Forsberg E" first="Elisabete" last="Forsberg">Elisabete Forsberg</name>
</region>
<name sortKey="Brismar, Kerstin" sort="Brismar, Kerstin" uniqKey="Brismar K" first="Kerstin" last="Brismar">Kerstin Brismar</name>
<name sortKey="Frosteg Rd, Johan" sort="Frosteg Rd, Johan" uniqKey="Frosteg Rd J" first="Johan" last="Frosteg Rd">Johan Frosteg Rd</name>
<name sortKey="Grunler, Jacob" sort="Grunler, Jacob" uniqKey="Grunler J" first="Jacob" last="Grünler">Jacob Grünler</name>
<name sortKey="K Rvestedt, Lars" sort="K Rvestedt, Lars" uniqKey="K Rvestedt L" first="Lars" last="K Rvestedt">Lars K Rvestedt</name>
<name sortKey="Tekle, Michael" sort="Tekle, Michael" uniqKey="Tekle M" first="Michael" last="Tekle">Michael Tekle</name>
<name sortKey="Xu, Cheng" sort="Xu, Cheng" uniqKey="Xu C" first="Cheng" last="Xu">Cheng Xu</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/GlutaredoxinV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000484 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000484 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    GlutaredoxinV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:26395643
   |texte=   Coenzyme Q10 and oxidative stress, the association with peripheral sensory neuropathy and cardiovascular disease in type 2 diabetes mellitus.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:26395643" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GlutaredoxinV1

This area was generated with Dilib version V0.6.37.
Data generation: Wed Nov 18 15:13:42 2020. Site generation: Wed Nov 18 15:16:12 2020

	Serveur d'exploration sur la glutarédoxine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la glutarédoxine

Coenzyme Q10 and oxidative stress, the association with peripheral sensory neuropathy and cardiovascular disease in type 2 diabetes mellitus.

Coenzyme Q10 and oxidative stress, the association with peripheral sensory neuropathy and cardiovascular disease in type 2 diabetes mellitus.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki